Top Section/Ad
Top Section/Ad
Most recent
◆ Praemia refis at a tighter coupon ◆ Schneider lands tight at the short end ◆ Minimal concessions needed
French biotech seeks to accelerate cancer vaccine program
◆ Single digit premiums offered ◆ Reverse Yankees dominating euro supply ◆ Floaters proving popular with multi-tranche issuers
Pair enjoyed strong execution and tight pricing as US high grade credit remained resilient in the face of a sell-off in equity markets
More articles/Ad
More articles/Ad
More articles
-
In a block trade, GSK sold 2.6% of its former joint venture with Pfizer -
After a blowout 2022, the pace of issuance in Saudi equity capital markets has slowed this year
-
Pipeline fills as foreign and domestic names prepare to print
-
Danish firm specialised in treatment for metabolic diseases issues 6.5m shares
-
UK pharma latest high rated company to hit the euro market this week
-
Rise of mRNA technology was a gamechanger for the sector, says analyst
